Pharnext has closed a strategic agreement with the Chinese company Tasly Pharmaceutical. The operation include a financial investment by Tasly in Pharnext, the development of a new pipeline of synergistic combinations through a shared platform and the license of Pharnext’s lead product for the Chinese market. PXT3003 is Pharnext’s lead product currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and has received the orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease.